Pharma BD Deal Intelligence
A win: Eli Lilly's $2.3B buyout of ICOS gave it full ownership of Cialis, a franchise that went on to generate $2.5B+ in peak annual sales and $20B+ in cumulative revenue. The full-control bet on a drug already validated through the prior joint venture paid off decisively.
Cialis JV buyout delivered exceptional ROI with $20B+ cumulative franchise revenue
Full analysis, sources & comparables →Lilly buys ICOS its Cialis partner for $2.1 billion to gain full control of the erectile dysfunction blockbuster generating $456M in first half 2006.
Press release issued by ICOS Corporation regarding Eli Lilly's offer to acquire all outstanding shares of ICOS common stock.
Lilly to acquire partner ICOS, gaining full control of Cialis, which broke through $1 billion in sales.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Eli Lilly acquired ICOS Corporation for $34 per share (approximately $2.3 billion), gaining full ownership of Cialis (tadalafil) which had been jointly marketed through the Lilly ICOS LLC joint venture since 2003. The initial offer of $32/share was raised after institutional shareholder pushback.
Adcirca (tadalafil 40mg once-daily) was FDA-approved in May 2009 for PAH (WHO Group 1) to improve exercise ability. The PAH competitive landscape groups into four MOA classes: PDE5 inhibitors, soluble guanylate cyclase (sGC) stimulators, endothelin receptor antagonists (ERAs), and prostacyclin pathway agents. In the PDE5i class, Revatio (sildenafil 20mg TID, Pfizer, approved 2005) is the direct comparator; Adcirca differentiated on once-daily dosing. Merck's Adempas (riociguat) is the only sGC stimulator (approved 2013) and is notably contraindicated with PDE5i due to hypotension risk, carving a switch-only dynamic. ERAs include J&J's Opsumit (macitentan, approved 2013, peak sales above $1.7B), Gilead's Letairis (ambrisentan, generic), and Actelion/J&J's Tracleer (bosentan, generic). Prostacyclin pathway agents comprise United Therapeutics' Tyvaso (inhaled treprostinil, approved 2009, roughly $1.5B 2023 sales), Remodulin (SC/IV treprostinil), Orenitram (oral treprostinil), Flolan/Veletri (epoprostenol, generic), and J&J's Uptravi (selexipag, IP receptor agonist). Merck's Winrevair (sotatercept, activin signaling inhibitor, approved March 2024) is the first novel-MOA PAH entrant in a decade and is reshaping combination practice. Commercial takeaway: Adcirca/generic tadalafil anchors foundational PDE5i therapy in combo regimens; franchise threat is low from direct MOA peers but high from sotatercept-driven treatment-paradigm shifts.
Cialis (tadalafil) was approved by the FDA in November 2003 for erectile dysfunction and became the second-largest PDE5 inhibitor globally, differentiated by its 36-hour half-life versus short-acting competitors. The competitive landscape groups by MOA class: PDE5 inhibitors (dominant), intraurethral/intracavernosal prostaglandins, and mechanical/non-pharmacologic options. In the PDE5i class, sildenafil (Viagra, Pfizer, first-to-market FDA 1998, peak branded sales approximately $2B) was the category pioneer and reference competitor; vardenafil (Levitra, Bayer/GSK, approved 2003) launched the same year as Cialis but failed to differentiate and was largely abandoned commercially after LOE; avanafil (Stendra, Vivus, approved 2012) was positioned as fastest-onset but never achieved meaningful share. Cialis differentiated on duration-of-action and secured a once-daily low-dose label (2008), which no competitor matched. In the prostaglandin E1 class, alprostadil delivered via intraurethral suppository (Muse, Meda/Viatris) or intracavernosal injection (Caverject, Pfizer; Edex, Endo) serves PDE5i non-responders as a small legacy segment. All three oral PDE5i have lost exclusivity; generic sildenafil (2017) and tadalafil (2018) have commoditized the market. Telehealth platforms (Hims, Roman) have disaggregated brand demand. Commercial takeaway: Cialis held the durable #2 PDE5i position pre-LOE on convenience differentiation; post-2018 the franchise value is captured almost entirely by generics and direct-to-consumer channels.
Cialis (tadalafil 5mg once-daily) was approved by the FDA in October 2011 for BPH signs and symptoms, making it the only PDE5 inhibitor labeled for BPH and expanding the ICOS-acquired asset into a second franchise. The competitive landscape groups by MOA class: alpha-1 adrenergic receptor antagonists, 5-alpha reductase inhibitors (5-ARIs), PDE5 inhibitors, and combination fixed-dose products. Alpha-blockers dominate first-line prescribing and include tamsulosin (Flomax, generic, historically >$1B peak brand sales, now commoditized), alfuzosin (Uroxatral, Sanofi, generic), silodosin (Rapaflo, Allergan/AbbVie), and doxazosin (Cardura, generic). 5-ARIs comprise finasteride (Proscar, Merck, generic) and dutasteride (Avodart, GSK, generic), used for volume reduction in larger prostates. In the combination FDC class, Jalyn (dutasteride + tamsulosin, GSK) is the anchor product. Cialis is the sole PDE5i with a BPH label; sildenafil (Viagra), vardenafil (Levitra), and avanafil (Stendra) are not BPH-approved. Following Cialis loss of exclusivity in 2017-2018, generic tadalafil has commoditized the PDE5i-for-BPH segment. The beta-3 agonist vibegron (Gemtesa, Sumitovant) is approved for OAB, not BPH. Commercial takeaway: Cialis-BPH carved a differentiated niche in patients with concomitant ED but faced immediate generic erosion post-LOE; the franchise threat came from commoditization, not branded competitors.
Eli Lilly and Company closes acquisition/merger of ICOS Corporation for $2.3B, establishing strategic position and initiating integration.
Eli Lilly acquired ICOS for $2.3B gaining full Cialis ownership which generated $2.5B+ peak annual sales and $20B+ cumulative revenue.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / ICOS Corporation (this deal) | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |
← Browse all deals · How we score deals
More: 2006 deals · Eli Lilly and Company deals · Cardiovascular deals